Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- Ono: Opalmon Tab, Long Allergy Season Boosts Sales 4.9%
November 21, 2005
- Astellas Seminar on Atopic Dermatitis
November 21, 2005
- Taisho: Slump of Self-medication Business Hurts Results
November 21, 2005
- REGULATORY NEWS IN BRIEF
November 21, 2005
- Marketing Remicade Aiming at 20,000 of 110,000 MTX Users: Tanabe Seiyaku
November 21, 2005
- So Far So Good: Dr Takenaka of Astellas
November 21, 2005
- Shionogi: Sales Up Just 1.6%; Crestor Boosts Profits
November 21, 2005
- Profits and CSR "Not Mutually Exclusive": Mr Mallet of Pfizer
November 21, 2005
- MCHD: MCC, MPC Post Growth in Sales and Profits
November 21, 2005
- Pfizer Health Research Forum
November 21, 2005
- Dainippon Sumitomo Enjoying "Smooth Start": Mr Miyatake
November 21, 2005
- R&D NEWS IN BRIEF
November 21, 2005
- Costs of Domestic Clinical Trials Remain Excessive: Mr Nakajima of JPMA
November 21, 2005
- FPMAJ, JPMA Petition on FY2006 Budget, Taxation System
November 21, 2005
- Korosho Political Tribe Concerned about Intimacy between Mr Kawasaki and Mr Tanigaki
November 14, 2005
- OPINION
November 14, 2005
- Council Members Insist on Deep Cuts into Medical Fees, NHI Prices
November 14, 2005
- Japanese Physicians Should More Positively Approach New Drug Development: Lilly's CMO A. Breier
November 14, 2005
- Reformists Criticize Korosho's Healthcare Reform Proposals
November 14, 2005
- Council Calls For Early Approval of 5 Global Standard Drugs Not Approved in Japan
November 14, 2005
ページ
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…